Greece

Greece

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.8 (1.65 - 1.97) 2019 Modelled IHME
1.8 (1.65 - 1.96) 2018 Modelled IHME
1.81 (1.63 - 1.97) 2017 Modelled IHME
1.81 (1.64 - 1.97) 2016 Modelled IHME
1.81 (1.64 - 2) 2015 Modelled IHME
1.82 (1.65 - 2) 2014 Modelled IHME
1.83 (1.67 - 2.01) 2013 Modelled IHME
1.84 (1.68 - 2.02) 2012 Modelled IHME
1.86 (1.69 - 2.04) 2011 Modelled IHME
1.87 (1.71 - 2.06) 2010 Modelled IHME
1.89 (1.73 - 2.07) 2009 Modelled IHME
1.91 (1.75 - 2.09) 2008 Modelled IHME
1.93 (1.77 - 2.10) 2007 Modelled IHME
1.95 (1.77 - 2.13) 2006 Modelled IHME
1.97 (1.78 - 2.16) 2005 Modelled IHME
1.99 (1.81 - 2.18) 2004 Modelled IHME
2.01 (1.83 - 2.20) 2003 Modelled IHME
2.03 (1.85 - 2.21) 2002 Modelled IHME
2.04 (1.87 - 2.24) 2001 Modelled IHME
2.06 (1.88 - 2.27) 2000 Modelled IHME
2.08 (1.90 - 2.28) 1999 Modelled IHME
2.1 (1.92 - 2.30) 1998 Modelled IHME
2.12 (1.94 - 2.33) 1997 Modelled IHME
2.14 (1.95 - 2.35) 1996 Modelled IHME
2.15 (1.95 - 2.37) 1995 Modelled IHME
2.17 (1.97 - 2.38) 1994 Modelled IHME
2.18 (1.98 - 2.40) 1993 Modelled IHME
2.2 (2 - 2.42) 1992 Modelled IHME
2.21 (2.01 - 2.44) 1991 Modelled IHME
2.22 (2.01 - 2.47) 1990 Modelled IHME
3.3 (2.20 - 4.70) 2010 Modelled Drositis I et al, 2013
1.14 (0.91 - 1.46) 2015 Modelled WHO
1.8 (1.50 - 2) 2016 Modelled Razavi-Shearer et al, 2018
0.97 (0.95 - 1) 2013 Modelled Schweitzer et al, 2015
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.05 (0.04 - 0.07) 2019 Modelled IHME
0.05 (0.04 - 0.07) 2018 Modelled IHME
0.05 (0.04 - 0.07) 2017 Modelled IHME
0.05 (0.04 - 0.07) 2016 Modelled IHME
0.05 (0.04 - 0.07) 2015 Modelled IHME
0.05 (0.04 - 0.07) 2014 Modelled IHME
0.05 (0.04 - 0.07) 2013 Modelled IHME
0.06 (0.04 - 0.07) 2012 Modelled IHME
0.06 (0.04 - 0.07) 2011 Modelled IHME
0.06 (0.04 - 0.08) 2010 Modelled IHME
0.06 (0.04 - 0.08) 2009 Modelled IHME
0.06 (0.05 - 0.08) 2008 Modelled IHME
0.07 (0.05 - 0.09) 2007 Modelled IHME
0.07 (0.05 - 0.09) 2006 Modelled IHME
0.07 (0.05 - 0.10) 2005 Modelled IHME
0.08 (0.06 - 0.10) 2004 Modelled IHME
0.08 (0.06 - 0.11) 2003 Modelled IHME
0.09 (0.07 - 0.12) 2002 Modelled IHME
0.1 (0.07 - 0.13) 2001 Modelled IHME
0.11 (0.09 - 0.14) 2000 Modelled IHME
0.18 (0.14 - 0.23) 1999 Modelled IHME
0.32 (0.25 - 0.42) 1998 Modelled IHME
0.49 (0.38 - 0.64) 1997 Modelled IHME
0.63 (0.49 - 0.82) 1996 Modelled IHME
0.71 (0.54 - 0.94) 1995 Modelled IHME
0.73 (0.55 - 0.96) 1994 Modelled IHME
0.75 (0.56 - 1) 1993 Modelled IHME
0.77 (0.57 - 1.02) 1992 Modelled IHME
0.78 (0.57 - 1.04) 1991 Modelled IHME
0.78 (0.57 - 1.05) 1990 Modelled IHME
0.37 (0.25 - 0.52) 2015 Modelled WHO
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
2.9 (2.40 - 3.50) 2003 Survey/reported Papaevangelou V et al, 2006
People who inject drugs (PWID)
Download
Value (%) Year Type Source
2.1 2017 Survey/reported ECDC
1.6 2016 Survey/reported EMCDDA
2.81 2015 Survey/reported EMCDDA
3.19 2014 Survey/reported EMCDDA
3.54 2013 Survey/reported EMCDDA
2.73 2012 Survey/reported EMCDDA
2.85 2015 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.75 2014 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.48 2013 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.27 2012 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.84 2011 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.89 2010 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.25 2009 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.71 2008 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.56 2006 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.34 2005 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.43 2004 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
2.33 2003 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
3.3 2002 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
4.3 2001 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) & University Mental Health Research Institute (UMHRI)
1.67 2015 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
1.88 2014 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
2.01 2013 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
1.32 2012 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
1.18 2011 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
3.64 2010 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
2.99 2009 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
2.26 2008 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
1.72 2006 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
3.09 2005 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
2.69 2004 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
5.84 2003 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
6.9 2002 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
4.8 2001 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
3.8 2000 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
3.5 1999 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
Showing out of
Show more
People who have ever injected drugs (PWID)
Download
Value (%) Year Type Source
2.1 2017 Survey/reported EMCDDA
Technical notes

Number of people living with chronic HBV

National
Download
Value Year Type Source
230,936 (208,801 - 256,741) 1990 Modelled IHME
231,267 (209,844 - 255,458) 1991 Modelled IHME
232,143 (210,854 - 255,826) 1992 Modelled IHME
232,539 (211,329 - 255,819) 1993 Modelled IHME
232,622 (211,544 - 255,678) 1994 Modelled IHME
232,503 (210,109 - 255,914) 1995 Modelled IHME
232,164 (211,695 - 255,128) 1996 Modelled IHME
231,685 (211,784 - 254,136) 1997 Modelled IHME
231,131 (210,801 - 253,494) 1998 Modelled IHME
230,044 (210,186 - 252,186) 1999 Modelled IHME
228,879 (208,513 - 251,696) 2000 Modelled IHME
227,770 (208,185 - 249,305) 2001 Modelled IHME
226,072 (206,161 - 247,162) 2002 Modelled IHME
223,935 (204,265 - 245,318) 2003 Modelled IHME
221,717 (201,783 - 243,205) 2004 Modelled IHME
219,547 (198,114 - 241,014) 2005 Modelled IHME
217,267 (197,831 - 237,620) 2006 Modelled IHME
214,807 (196,867 - 234,425) 2007 Modelled IHME
212,393 (194,882 - 232,376) 2008 Modelled IHME
210,062 (192,636 - 230,214) 2009 Modelled IHME
207,673 (188,965 - 228,397) 2010 Modelled IHME
204,844 (186,629 - 224,419) 2011 Modelled IHME
201,301 (183,553 - 220,482) 2012 Modelled IHME
197,648 (180,026 - 216,499) 2013 Modelled IHME
194,524 (176,635 - 213,575) 2014 Modelled IHME
191,990 (173,372 - 211,533) 2015 Modelled IHME
190,231 (172,952 - 207,097) 2016 Modelled IHME
188,943 (170,375 - 205,909) 2017 Modelled IHME
187,532 (172,093 - 203,806) 2018 Modelled IHME
185,964 (170,082 - 203,812) 2019 Modelled IHME
200,000 (168,000 - 222,000) 2016 Modelled Razavi-Shearer et al, 2018
Showing out of
Show more

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
3.6 (2.89 - 4.48) 2019 Modelled IHME
3.59 (2.89 - 4.42) 2018 Modelled IHME
3.56 (2.87 - 4.40) 2017 Modelled IHME
3.55 (2.83 - 4.34) 2016 Modelled IHME
3.5 (2.79 - 4.29) 2015 Modelled IHME
3.5 (2.80 - 4.27) 2014 Modelled IHME
3.67 (2.98 - 4.45) 2013 Modelled IHME
3.65 (2.99 - 4.39) 2012 Modelled IHME
3.53 (2.90 - 4.25) 2011 Modelled IHME
3.37 (2.76 - 4.03) 2010 Modelled IHME
3.3 (2.70 - 3.93) 2009 Modelled IHME
3.25 (2.64 - 3.90) 2008 Modelled IHME
3.42 (2.80 - 4.13) 2007 Modelled IHME
3.37 (2.72 - 4.10) 2006 Modelled IHME
3.33 (2.68 - 4.07) 2005 Modelled IHME
3.23 (2.60 - 3.95) 2004 Modelled IHME
3.21 (2.58 - 3.91) 2003 Modelled IHME
3.17 (2.56 - 3.87) 2002 Modelled IHME
3.17 (2.54 - 3.89) 2001 Modelled IHME
3.18 (2.54 - 3.89) 2000 Modelled IHME
3.18 (2.55 - 3.91) 1999 Modelled IHME
3.14 (2.53 - 3.86) 1998 Modelled IHME
3.1 (2.48 - 3.82) 1997 Modelled IHME
3.11 (2.49 - 3.83) 1996 Modelled IHME
3.12 (2.50 - 3.85) 1995 Modelled IHME
3.13 (2.47 - 3.88) 1994 Modelled IHME
3.14 (2.48 - 3.91) 1993 Modelled IHME
3.17 (2.51 - 3.95) 1992 Modelled IHME
3.13 (2.47 - 3.91) 1991 Modelled IHME
3.11 (2.43 - 3.91) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
372 (299 - 463) 2019 Modelled IHME
374 (300 - 460) 2018 Modelled IHME
373 (300 - 460) 2017 Modelled IHME
373 (297 - 457) 2016 Modelled IHME
370 (296 - 455) 2015 Modelled IHME
374 (299 - 457) 2014 Modelled IHME
396 (322 - 481) 2013 Modelled IHME
398 (326 - 479) 2012 Modelled IHME
389 (320 - 468) 2011 Modelled IHME
373 (306 - 447) 2010 Modelled IHME
366 (300 - 437) 2009 Modelled IHME
361 (294 - 434) 2008 Modelled IHME
381 (312 - 460) 2007 Modelled IHME
376 (303 - 457) 2006 Modelled IHME
372 (299 - 455) 2005 Modelled IHME
361 (290 - 440) 2004 Modelled IHME
358 (288 - 436) 2003 Modelled IHME
354 (286 - 432) 2002 Modelled IHME
353 (283 - 433) 2001 Modelled IHME
353 (281 - 432) 2000 Modelled IHME
352 (281 - 432) 1999 Modelled IHME
346 (278 - 425) 1998 Modelled IHME
338 (271 - 418) 1997 Modelled IHME
338 (270 - 416) 1996 Modelled IHME
337 (270 - 416) 1995 Modelled IHME
335 (265 - 416) 1994 Modelled IHME
335 (264 - 416) 1993 Modelled IHME
334 (265 - 417) 1992 Modelled IHME
327 (258 - 409) 1991 Modelled IHME
324 (253 - 406) 1990 Modelled IHME
967 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
32 (24 - 42) 2019 Modelled IHME
32 (24 - 42) 2018 Modelled IHME
32 (24 - 42) 2017 Modelled IHME
32 (24 - 42) 2016 Modelled IHME
32 (24 - 42) 2015 Modelled IHME
32 (24 - 42) 2014 Modelled IHME
32 (24 - 43) 2013 Modelled IHME
32 (24 - 42) 2012 Modelled IHME
32 (24 - 42) 2011 Modelled IHME
32 (24 - 42) 2010 Modelled IHME
32 (24 - 42) 2009 Modelled IHME
32 (24 - 42) 2008 Modelled IHME
33 (24 - 43) 2007 Modelled IHME
34 (25 - 44) 2006 Modelled IHME
34 (25 - 44) 2005 Modelled IHME
34 (25 - 44) 2004 Modelled IHME
34 (25 - 44) 2003 Modelled IHME
34 (25 - 44) 2002 Modelled IHME
34 (25 - 44) 2001 Modelled IHME
34 (25 - 44) 2000 Modelled IHME
34 (25 - 44) 1999 Modelled IHME
34 (25 - 44) 1998 Modelled IHME
34 (25 - 44) 1997 Modelled IHME
34 (25 - 44) 1996 Modelled IHME
34 (25 - 44) 1995 Modelled IHME
34 (25 - 44) 1994 Modelled IHME
34 (25 - 43) 1993 Modelled IHME
34 (25 - 43) 1992 Modelled IHME
34 (25 - 43) 1991 Modelled IHME
34 (25 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2019 Survey/reported WHO/UNICEF
96 2020 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
76 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
76 2017 Survey/reported ECDC
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.61 (0.50 - 0.75) 2019 Modelled IHME
0.61 (0.50 - 0.74) 2018 Modelled IHME
0.6 (0.49 - 0.74) 2017 Modelled IHME
0.59 (0.49 - 0.73) 2016 Modelled IHME
0.58 (0.47 - 0.72) 2015 Modelled IHME
0.57 (0.47 - 0.71) 2014 Modelled IHME
0.57 (0.47 - 0.70) 2013 Modelled IHME
0.56 (0.46 - 0.69) 2012 Modelled IHME
0.56 (0.46 - 0.69) 2011 Modelled IHME
0.56 (0.46 - 0.68) 2010 Modelled IHME
0.55 (0.45 - 0.68) 2009 Modelled IHME
0.55 (0.45 - 0.68) 2008 Modelled IHME
0.55 (0.45 - 0.68) 2007 Modelled IHME
0.54 (0.44 - 0.68) 2006 Modelled IHME
0.54 (0.44 - 0.67) 2005 Modelled IHME
0.52 (0.43 - 0.64) 2004 Modelled IHME
0.48 (0.40 - 0.59) 2003 Modelled IHME
0.44 (0.36 - 0.54) 2002 Modelled IHME
0.41 (0.34 - 0.49) 2001 Modelled IHME
0.39 (0.32 - 0.48) 2000 Modelled IHME
0.39 (0.32 - 0.47) 1999 Modelled IHME
0.4 (0.33 - 0.47) 1998 Modelled IHME
0.4 (0.33 - 0.48) 1997 Modelled IHME
0.4 (0.33 - 0.48) 1996 Modelled IHME
0.41 (0.34 - 0.49) 1995 Modelled IHME
0.42 (0.35 - 0.50) 1994 Modelled IHME
0.45 (0.37 - 0.54) 1993 Modelled IHME
0.48 (0.40 - 0.58) 1992 Modelled IHME
0.53 (0.44 - 0.64) 1991 Modelled IHME
0.58 (0.47 - 0.71) 1990 Modelled IHME
1.1 (0.70 - 1.50) 2015 Modelled Blach et al, 2017
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
54.82 2015 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
66.67 2014 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
55.6 2013 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
59.63 2012 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
62.36 2011 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
48.7 2010 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
43.46 2009 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
44.87 2008 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
42.63 2006 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
43.28 2005 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
44.19 2004 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
35.83 2003 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
40.8 2002 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
37.9 2001 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
40.1 2000 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
51.7 1999 Survey/reported EMCDDA; Therapy Center for Dependent Individuals (KETHEA)
63.5 2016 Survey/reported EMCDDA
61.52 2015 Survey/reported EMCDDA
68.71 2014 Survey/reported EMCDDA
65.57 2013 Survey/reported EMCDDA
70.29 2012 Survey/reported EMCDDA
69.61 2015 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
73.45 2014 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
74.4 2013 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
73.42 2012 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
69.35 2011 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
69.3 2010 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
64.26 2009 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
55.46 2008 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
66.02 2006 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
61.72 2005 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
61.18 2004 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
67.2 2003 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
62 2002 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
67.9 2001 Survey/reported EMCDDA; Greek REITOX Focal Point (EKTEPN) &University Mental Health Research Institute (UMHRI).
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
0.38 (0.24 - 0.49) 2019 Modelled Dugan et al., 2021
Technical notes

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2.2 (1.30 - 3.40) 2010 Survey/reported Drositis et al, 2013
1.9 (0.50 - 2.60) 2014 Survey/reported Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
65.7 (61.80 - 69.50) 2014 Modelled Degenhardt L et al, 2017
68.1 (65.50 - 70.60) 2013 Survey/reported EMCDDA
66.5 2017 Survey/reported ECDC
Showing out of
Show more
People who have ever injected drugs (PWID)
Download
Value (%) Year Type Source
66.5 2017 Survey/reported EMCDDA
Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National
Download
Value Year Type Source
60,222 (49,155 - 73,424) 1990 Modelled IHME
55,438 (45,551 - 66,983) 1991 Modelled IHME
51,171 (42,686 - 61,541) 1992 Modelled IHME
47,539 (39,782 - 57,147) 1993 Modelled IHME
44,966 (37,379 - 53,897) 1994 Modelled IHME
43,861 (36,282 - 52,755) 1995 Modelled IHME
43,654 (36,080 - 52,303) 1996 Modelled IHME
43,536 (35,991 - 52,315) 1997 Modelled IHME
43,523 (35,790 - 52,216) 1998 Modelled IHME
43,527 (35,719 - 52,416) 1999 Modelled IHME
43,637 (35,618 - 52,760) 2000 Modelled IHME
45,408 (37,523 - 55,106) 2001 Modelled IHME
49,322 (40,618 - 59,978) 2002 Modelled IHME
53,989 (44,383 - 66,252) 2003 Modelled IHME
58,067 (47,899 - 71,772) 2004 Modelled IHME
60,180 (49,233 - 75,101) 2005 Modelled IHME
60,702 (49,583 - 75,366) 2006 Modelled IHME
61,011 (49,745 - 75,452) 2007 Modelled IHME
61,230 (50,108 - 75,444) 2008 Modelled IHME
61,429 (50,313 - 75,441) 2009 Modelled IHME
61,623 (50,629 - 75,364) 2010 Modelled IHME
61,718 (50,716 - 75,598) 2011 Modelled IHME
61,602 (50,603 - 75,776) 2012 Modelled IHME
61,443 (50,466 - 75,655) 2013 Modelled IHME
61,425 (50,480 - 75,833) 2014 Modelled IHME
61,560 (50,214 - 76,029) 2015 Modelled IHME
62,374 (51,080 - 77,154) 2016 Modelled IHME
63,162 (51,405 - 77,762) 2017 Modelled IHME
63,239 (51,733 - 77,155) 2018 Modelled IHME
63,040 (51,357 - 77,202) 2019 Modelled IHME
132,000 (82,000 - 169,000) 2015 Modelled Blach et al, 2017
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value Year Type Source
8,500 (5,300 - 10,900) 2019 Modelled Dugan et al., 2021

HCV-related death rate

National
Download
Value (Deaths per 100,000) Year Type Source
3.84 (2.96 - 4.85) 2019 Modelled IHME
3.78 (2.95 - 4.73) 2018 Modelled IHME
3.67 (2.84 - 4.57) 2017 Modelled IHME
3.63 (2.81 - 4.53) 2016 Modelled IHME
3.55 (2.76 - 4.45) 2015 Modelled IHME
3.49 (2.70 - 4.37) 2014 Modelled IHME
3.46 (2.68 - 4.35) 2013 Modelled IHME
3.4 (2.64 - 4.33) 2012 Modelled IHME
3.27 (2.54 - 4.19) 2011 Modelled IHME
3.15 (2.45 - 4.01) 2010 Modelled IHME
3.09 (2.41 - 3.95) 2009 Modelled IHME
3 (2.33 - 3.84) 2008 Modelled IHME
2.94 (2.29 - 3.80) 2007 Modelled IHME
2.81 (2.18 - 3.65) 2006 Modelled IHME
2.78 (2.15 - 3.61) 2005 Modelled IHME
2.77 (2.14 - 3.58) 2004 Modelled IHME
2.79 (2.16 - 3.61) 2003 Modelled IHME
2.79 (2.17 - 3.62) 2002 Modelled IHME
2.83 (2.20 - 3.66) 2001 Modelled IHME
2.86 (2.22 - 3.70) 2000 Modelled IHME
2.9 (2.22 - 3.75) 1999 Modelled IHME
2.92 (2.23 - 3.77) 1998 Modelled IHME
2.95 (2.26 - 3.84) 1997 Modelled IHME
3.01 (2.28 - 3.93) 1996 Modelled IHME
3.06 (2.32 - 3.99) 1995 Modelled IHME
3.13 (2.35 - 4.08) 1994 Modelled IHME
3.21 (2.42 - 4.21) 1993 Modelled IHME
3.29 (2.48 - 4.31) 1992 Modelled IHME
3.27 (2.46 - 4.31) 1991 Modelled IHME
3.28 (2.47 - 4.31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
397 (306 - 502) 2019 Modelled IHME
393 (306 - 492) 2018 Modelled IHME
384 (297 - 478) 2017 Modelled IHME
382 (296 - 476) 2016 Modelled IHME
376 (292 - 472) 2015 Modelled IHME
373 (289 - 467) 2014 Modelled IHME
373 (289 - 470) 2013 Modelled IHME
371 (288 - 473) 2012 Modelled IHME
361 (280 - 462) 2011 Modelled IHME
349 (271 - 445) 2010 Modelled IHME
344 (267 - 439) 2009 Modelled IHME
334 (259 - 427) 2008 Modelled IHME
327 (255 - 423) 2007 Modelled IHME
314 (243 - 407) 2006 Modelled IHME
310 (240 - 403) 2005 Modelled IHME
309 (239 - 399) 2004 Modelled IHME
311 (241 - 402) 2003 Modelled IHME
312 (242 - 405) 2002 Modelled IHME
315 (245 - 408) 2001 Modelled IHME
317 (246 - 411) 2000 Modelled IHME
321 (246 - 414) 1999 Modelled IHME
321 (246 - 415) 1998 Modelled IHME
322 (247 - 420) 1997 Modelled IHME
327 (248 - 427) 1996 Modelled IHME
330 (251 - 431) 1995 Modelled IHME
336 (252 - 438) 1994 Modelled IHME
342 (257 - 448) 1993 Modelled IHME
347 (262 - 456) 1992 Modelled IHME
342 (258 - 451) 1991 Modelled IHME
341 (257 - 448) 1990 Modelled IHME
527 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (15 - 28) 2019 Modelled IHME
21 (15 - 28) 2018 Modelled IHME
21 (15 - 28) 2017 Modelled IHME
21 (14 - 28) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 26) 2007 Modelled IHME
19 (14 - 26) 2006 Modelled IHME
19 (13 - 26) 2005 Modelled IHME
19 (14 - 25) 2004 Modelled IHME
19 (14 - 25) 2003 Modelled IHME
19 (13 - 25) 2002 Modelled IHME
19 (13 - 25) 2001 Modelled IHME
19 (13 - 25) 2000 Modelled IHME
19 (13 - 25) 1999 Modelled IHME
19 (14 - 25) 1998 Modelled IHME
19 (14 - 26) 1997 Modelled IHME
19 (14 - 26) 1996 Modelled IHME
19 (14 - 26) 1995 Modelled IHME
19 (14 - 26) 1994 Modelled IHME
19 (14 - 26) 1993 Modelled IHME
19 (14 - 26) 1992 Modelled IHME
20 (14 - 26) 1991 Modelled IHME
20 (14 - 27) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
76 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
76 2017 Survey/reported ECDC
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Source: WHO
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Source: WHO

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.8 (%)
2019
(1.65 - 1.97(%))
IHME
HCV (RNA/cAg+)
0.61 (%)
2019
(0.5 - 0.75(%))
IHME

Survey/surveillance

No data available
HCV (anti-HCV)
1.9 (%)
2014
(0.5 - 2.6(%))
Gower et al, 2014

Hepatitis related deaths (national)

Modelled

HBV
372
2019
(299 - 463)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
397
2019
(306 - 502)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.05 (%)
2019, latest modelled
(0.04 - 0.07(%))
IHME

Prevalence PWID

HCV
66.50 (%)
2017, survey/surveillance
ECDC

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
76
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources